Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human, Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of ARX305 in adults with clear cell renal cell carcinoma who are resistant or refractory to prior standard therapies

Next Previous
Search
Trial Profile

A first in human, Phase 1, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of ARX305 in adults with clear cell renal cell carcinoma who are resistant or refractory to prior standard therapies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ARX 305 (Primary)
  • Indications Haematological malignancies; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 09 Nov 2022 Accordig to an Ambrx media release, first patient has been dosed in this trial.
    • 09 Nov 2022 Status changed from planning to recruiting, according to an Ambrx media release.
    • 01 Jul 2022 Accordig to an Ambrx media release, In July, Ambrxs partner in China, NovoCodex, announced that it had received drug clinical trial approval notice for ARX305 and intends to initiate this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top